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Abstract 
The direct oral anticoagulants emerge as the most innovative and promising drugs 
towards preventing and treating cardiovascular disease, raising great interest among the 
scientific community.  
Numerous studies and meta-analysis generated many data clarifying clinicians’ doubts; 
however, there are remaining uncertainties regarding their use in particular groups such 
as patients with prosthetic valves, in valvular atrial fibrillation (defined as atrial 
fibrillation related to mitral rheumatic heart disease or prosthetic heart valves), among 
the elderly, in paraneoplastic thromboembolism, in pulmonary embolism with 
hemodynamic compromise, and the scarcity of specific antidotes. 
This review article intends to condense the vast scientific production addressing new 
oral anticoagulants by focusing on their advantages and disadvantages when used on the 
elderly. 
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Introduction 
The increase in lifespan created what probably is the greatest challenge in modern 
medicine: to prolong the quantity of life years while maintaining the quality of life. 
This challenge determines that invasive diagnostic and therapeutic methods should be 
implemented, as well as the latest technology in individuals once called “elderly”. 
Ageing, as a result of better healthcare, has motivated important social changes that led 
to a paradigm change in medical practice: advanced aged now represents just another 
individual characteristic and not a limiting factor for clinical investment.  
Bearing this in mind, the authors address the use of new oral anticoagulants in the 
elderly, stressing its advantages and disadvantages, and putting it into context with the 
singularities of this age group.   
 
The complexity of anticoagulating the elderly 
The decision of anticoagulating an individual with advanced age (a person over 80 years 
of age according to the World Health Organization)
1
 is quite complex, since important  
factors should be taken into consideration in this particular group, for instance impaired 
cognition that limits drug adherence and potentiates the risk of falls. 
The high prevalence of comorbidities that increase the hemorrhagic risk (cancer, 
hepatic, hematological and gastrointestinal diseases) and diseases that simultaneously 
constitute an indication for anticoagulation but also a risk factor for bleeding (arterial 
hypertension and ischemic stroke, according to the risk scores CHA2DS2VASc
2,3
 and 
HASBLED
4
) are to be considered. 
Chronic kidney disease (CKD) as well as low body weight, frequently involve dosing 
adjustments. 
Another singularity in this population is polymedication which significantly contributes 
to the increased risk of pharmacological interactions.  
Advanced age per se is, paradoxically, an independent risk factor for thromboembolism 
and hemorrhagic dyscrasia, impairing the delicate hemostatic balance.
5,6
 
According to the thromboembolic risk score CHA2DS2VASc (anticoagulate if score > 2 
points), age ≥65 years scores 1 point and the score is doubled if ≥75 years old.2,3,7 As 
such, it is evident that age plays a key role in this score, and being ≥75 years old is by 
itself a formal indication for anticoagulation considering that no contraindications are 
present. 
Nevertheless, age ≥65 years is a risk factor according to the hemorrhagic risk score 
HASBLED.
4
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As clinicians, it is our responsibility to evaluate the benefit of anticoagulating and to 
judiciously decide which drug suits best each patient. How can we overcome this 
dilemma? 
New oral anticoagulants (NOAC) seem to be an appealing alternative to traditional 
anticoagulation.  
The discovery of these molecules had such an impact that it justified the review, in 
2012, of the European Society of Cardiology non valvular atrial fibrillation (defined as 
atrial fibrillation not associated with rheumatic valvular disease nor prosthetic heart 
valves) guidelines.
8
  
 
Pharmacokinetics and pharmacodynamics 
Physiological factors like age, body weight, nutritional status and renal function, and 
clinical factors such as acute illnesses and drug interaction are well known determinants 
of the pharmacokinetics/ pharmacodynamics balance of a drug. 
Medicating the elderly, often a group characterized for being frail, for suffering from 
multiple comorbidities, polymedicated and prone to clinical decompensation requires a 
stricter surveillance than the general population as the metabolism and elimination of 
many drugs are impaired, requiring dose adjustment in order to avoid toxicity.  
NOACs directly and selectively inhibit a coagulation pathway enzyme (thrombin/factor 
IIa or factor Xa)
8
 in opposition to coumarins that inhibit vitamin K-dependent 
coagulation factors (II,VII, IX and X)
9
 and heparins that act primarily by activating 
antithrombin.
10
 
Due to this mechanism of action, these drugs are also called direct oral anticoagulants 
(DOAC) or target-specific oral anticoagulants (TSOAC). 
Dabigatran is a direct thrombin inhibitor (DTI), while rivaroxaban, apixaban and 
edoxaban inhibit factor Xa.  
These drugs present predictable pharmacokinetics (PK), characterized by a fast onset of 
action, a short half-life and a wide therapeutic window, allowing a safe use without 
frequent monitoring.
9,11
  
In the elderly with drug compliance limitations, the need for regular monitoring of 
anticoagulation levels due to the narrow therapeutic window of coumarin 
anticoagulants, in addition to the need of achieving a time in the therapeutic range 
(TTR) >70% to ensure appropriate efficacy, represents a major disadvantage for vitamin 
K antagonists (VKA) comparing to NOAC.
7,12
  
In individuals with a TTR <70% or labile INR values, despite a good compliance, it 
may be pertinent to start a NOAC as long as the patients do not belong to the previously 
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described groups. The SAMe-TT2R2 score allows an estimation of the anticoagulation 
quality with coumarins in atrial fibrillation (AF), considering values between 0 and 1 to 
be adequate.
13
 
 
Transition between anticoagulants 
NOACs reach peak concentrations 1-4 hours after administration, which means that no 
bridging period with heparins is needed while transitioning from VKA to these new 
drugs.
14
 
In the clinical trial ROCKET AF, the patients that stopped VKA and started rivaroxaban 
when the INR dropped <3, had similar outcomes as the group that started rivaroxaban 
de novo.
15,16
 
Regarding dabigatran
17
 and apixaban
18 
it is recommended to start these drugs when the 
INR drops <2 after discontinuing the VKA. It is suggested to start edoxaban when INR 
≤ 2.5.19  
Considering that NOACs have a short half-life (12-14 hours for dabigatran
20,21
, 5-13 
hours for rivaroxaban
22
, 8-15 hours for apixaban
10
 and 6-10 hours for edoxaban
10
) 
compared to warfarin, which can reach a terminal half-life of up to 160 hours
9
, it is 
speculated that an increased thromboembolic risk may be present during the transition 
to VKA. 
The increased stroke risk verified in the ROCKET AF trial when patients were switched 
to VKA in the end of the trial, supports this suspicion.
23
 
The scarce available evidence regarding the transition from NOACs to VKAs
10
, 
suggests the start of VKA three days before suspending dabigatran if creatinine 
clearance (CrCl) > 50 mL/min, two days before if CrCl between 30-50 mL/min and one 
day before if CrCl between 15-30 mL/min.
24
  
For rivaroxaban it is recommended to start the VKA four, three or two days before 
suspending the factor Xa inhibitor, respectively, considering the above mentioned CrCl 
intervals.
24
 
Both for apixaban and edoxaban it is recommended to start the VKA and maintain the 
co-administration of the NOAC until the INR reaches values ≥ 2.18,19  
The paucity of robust data addressing the transition between anticoagulants is 
furthermore complicated by the fact that the PK of the NOACs is altered and their half-
life is prolonged in the elderly (the area under the concentration-time curve of 
dabigatran is increased twofold
20
, for apixaban
18
 there is a 33% increase and concerning 
rivaroxaban the half-life sets around 11-13 hours
22
). 
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Chronic kidney disease and low body weight 
Renal excretion is a major elimination route for NOAC.
9,10
 In CKD the half-life of these 
drugs is prolonged, therefore the European Heart Rhythm Association (EHRA) 
contraindicates the use of dabigatran if CrCl<30mL/min and in end-stage renal disease 
(CrCl<15mL/min) regarding the factor Xa direct inhibitors.
25
 
The prevalence of CKD in the elderly may pose a limitation to NOACs use in this 
population.
26
   
The pro-drug dabigatran etexilate is converted to the active drug dabigatran in the liver, 
presenting a longer clearance in CKD and in the elderly.
17
 Considering this, the 
European Medical Agency (EMA) suggests a dose reduction (110 mg BID instead of 
150 mg BID) in individuals over 80 years old, contraindicating this drug if the 
glomerular filtration rate (GFR) is below 30 ml/min.
20,26 
 
Regarding rivaroxaban, it is suggested a dose reduction from 20 mg/day to 15 mg/day if 
GFR 15-49 mL/min, and it is contraindicated if the GFR is below 15 ml/min.
22,26
 
For apixaban, a dose reduction from 5 mg BID to 2.5 mg BID is suggested if at least 2 
of the 3 following criteria are present: age ≥ 80 years, body weight ≤ 60 kg, serum 
creatinine ≥ 1.5 mg/dl. The same dose is suggested if GFR is between 15–29 mL/min. 
Patients with a creatinine clearance < 15 ml/min should not take this drug as mentioned 
before.
18,26
  
With edoxaban, the standard dose is 60 mg/day and a dose reduction to half is 
recommended in patients with GFR between 50 and 15 mL/min or with a body weight ≤ 
60 kg. It is contraindicated if GFR is < 15 ml/min.
19,27
  
Betrixaban, a factor Xa inhibitor mainly excreted in bile is still undergoing phase III 
trials and could overcome some of the limitations of NOACs in severe CKD.
28
 
 
Pharmacological interactions 
The elderly are usually polymedicated and could therefore benefit from NOACs since 
they present a reduced pharmacological interaction potential compared to VKA.
9,10,29
 
Despite this, one must consider certain aspects.  
Drugs that simultaneously inhibit CYP-3A4 and P-glycoprotein (systemic imidazole 
derivatives, tacrolimus, cyclosporine and ritonavir) increase apixaban and rivaroxaban 
bioavailability, and therefore its concomitant use is not recommended.
18,22
   
Regarding edoxaban, its co-administration with rifampicin is contraindicated and a dose 
reduction to 30 mg/day is recommended if taken concomitantly with drugs that interfere 
with P-glycoprotein (including weak competitors such as amiodarone, diltiazem, 
verapamil, dronedarone, quinidine and macrolides).
19,27,30
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Since dabigatran is not metabolized by CYP450, it has a limited potential for 
pharmacological interactions; nonetheless, its PK may vary due to the concomitant use 
of drugs that modulate the action of the efflux transporter P-glycoprotein. It is 
recommended a dose reduction to 110 mg twice daily if taken simultaneously with 
verapamil.
20
  
In a patient population prone to infections it may be preferable to use a NOAC instead 
of a VKA, since the effect of the latter may be potentiated by antibiotics that eliminate 
intestinal vitamin K-producing bacteria.
9,31
 
Although quinolones are considered as the antibiotics that most frequently interfere with 
VKAs, exposure to other classes of antibiotics (penicillins, cephalosporins, macrolides, 
cotrimoxazole) and inclusively antimycotics (imidazole derivatives) encompasses an 
augmented hemorrhagic risk.
9,32 
 
The overestimation of the hemorrhagic risk 
A variable that weighs in the risk-benefit equation of anticoagulating the elderly is their 
increased sensibility to coumarins. It is speculated that a reduced clearance of the VKAs 
and/or a greater inhibition of vitamin K-dependent coagulation factors may justify 
this.
33
  
Furthermore, the elderly sometimes have nutritional deficits, namely a poor vitamin K 
diet that also enhances the coumarins’ hemorrhagic risk.9 Alcohol consumption also 
affects VKAs’ efficacy.9 Regarding the NOACs, rivaroxaban should be taken along 
with food as food  ingestion influences its absorption and bioavailability by increasing 
its area under the curve plasma concentrations by 39%.
25
 
Moreover, there is also the idiosyncratic variation of these drugs, based on the genetic 
polymorphism of CYP-2C9, which is responsible for VKA metabolization.
9
 
The overall hemorrhagic risk (the sum of major and non-major bleedings) in clinical 
trials comparing NOACs and warfarin was similar, or even inferior in the NOACs’ arm, 
as demonstrated in a meta-analysis that included over 70 000 patients.
34
 
In these studies, the major bleeding risk (defined as an hemoglobin drop ≥ 2g/dl, need 
for ≥ 2 units of  whole blood or packed red blood cells, and/or bleeding in a critical 
location) was about 2-3% per year, and was comparable to the risk of warfarin-treated 
patients.
15,27,30,35,36
  
A meta-analysis that included 10 studies with dabigatran, rivaroxaban or apixaban in 
stroke prevention in atrial fibrillation and  acute venous thromboembolism (VTE) 
prevention, specifically in patients ≥ 75 years, showed a greater efficacy in favor of 
NOACs (vs traditional anticoagulants) with a comparable risk for major or non-major 
clinically relevant bleeding.
37
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Considering deep vein thrombosis (DVT), a meta-analysis documented a reduction by 
half in the risk of fatal bleeding in patients treated with a NOAC.
38
 
In patients aged < 75, dabigatran presented a dose-independent inferior bleeding risk, 
while in patients > 75 years the risk of major extracranial bleeding was similar between 
the 110 mg BID dose and warfarin, and greater with the 150 mg BID dose due to the 
increased risk of gastrointestinal (GI) bleeding.
39
  
Concerning apixaban the bleeding risk was inferior independent of age.
36
 
The risk of major GI bleeding was also greater with rivaroxaban
15
 and edoxaban.
30
  
It should be pointed out that the annual incidence of intracranial bleeding with NOACs 
ranged from 0.1-0.5%, which is quite lower than the incidence with coumarins, and that 
the reduction in fatal bleeding is intimately correlated with the decrease in intracranial 
bleeding.
34
  
Considering that the major and most feared complication of anticoagulation is 
intracranial bleeding, which accounts for 90% of all warfarin-related deaths, this should 
be the strongest argument in favor of NOACs use.
40,41
 
Advanced age is, aside from arterial hypertension, the major risk factor for spontaneous 
intracranial bleeding.
42,43
 
The incidence of spontaneous intracranial bleeding in elderly aged 70-80 years is about 
0.15% per year, increasing to 0.3-0.8% per year if these individuals are anticoagulated; 
nonetheless, the benefit of stroke reduction due to anticoagulation outweighs that 
risk.
44,45,46
 
The risk of fall-related subdural haematoma is so low that an anticoagulated AF patient 
with an average stroke risk (estimated to be 5% per year) would have to fall 300 times 
per year so that the risk of bleeding outweighed the benefit of being under 
antithrombotic treatment.
33
  
 
The scarcity of specific antidotes 
Bearing in mind that the major complication for anticoagulation is hemorrhagic 
dyscrasia, the scarcity of available antidotes for NOACs, unlike coumarins and heparins 
(that can have their effect reverted with phytomenadione/vitamin K or protamine 
sulphate, respectively) may pose a limitation to its use.
10,14, 26,47,48, 49
 
Activated charcoal and prothrombin complex appear as alternatives to a specific 
antidote, while antagonists to these molecules still undergo further development.
10,20
 
Fresh frozen plasma and phytomenadione, on the other hand, have revealed lack of 
efficacy neutralizing NOACs.
10
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In patients on dabigatran presenting with major bleeding, hemodialysis eliminated about 
60% of the circulating DTI.
9
 
The only available antidote, recently approved by the Food and Drug Administration 
(FDA) based on the RE-VERSE AD trial, is the human antibody fragment idarucizumab 
that inhibits dabigatran.
50
 
A factor Xa analogue that reverses the effect of its inhibitors is still under 
development.
51
  
The anticoagulant effect of NOACs cannot be monitored precisely with routine 
laboratory tests.
10,52
 There are very specific analysis such as thrombin and ecarin 
clotting time which accurately estimate the effect of dabigatran, and the decrease of 
anti-Xa activity (that evaluates the Xa inhibitors’ effect), however, its availability is 
scarce and only few centers have it by routine.
52
 
Although NOACs present stable PK and PD, enabling the use of fixed doses without 
frequent monitoring, their use requires vigilance bearing in mind their potentially severe 
complications. The EHRA advocates regular follow-up based on the patient profile, 
such as periodical renal function evaluation in the elderly and frail patients.
25
  
Some particular circumstances may also demand laboratory re-evaluation, namely the 
introduction of drugs that may interfere with their effect and acute clinical conditions 
that may alter the CrCl.
25 
This Association also recommends systematic laboratory testing and thorough 
examination of dyscrasia signs in the specific setting of patients with cancer submitted 
to chemotherapy and radiotherapy.
25 
Besides these situations it is reasonable to perform coagulation tests in emergency 
scenarios such as an overdose suspicion and patients undergoing an urgent surgical 
procedure.
25
 
It should be emphasized that in this less compliant population regular laboratory testing 
could be justifiable given the short half-lives of the NOACs. 
 
An undertreated high-risk population 
Despite all the evidence about the benefit of anticoagulating the elderly with AF, 
particularly regarding stroke reduction, this population continues to be 
undertreated.
44,45,46
 
Some series estimate that only 30 to 50% of the elderly without contraindication for 
anticoagulation are effectively under treatment.
53,54
 
Advanced age is an independent risk factor for developing AF, and it is likely that 5-
15% of individuals aged > 80 suffer from this arrhythmia. It is estimated that by 2050 
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half of the patients with AF will be over 80 years old.
55
 According to a Framingham 
study 23.5 % of strokes in patients that age are due to AF.
56
 
Currently about 70% of patients with AF are aged between 65 and 85 years.
57
 
In individuals with AF, age ≥ 75 is the main risk factor for the development of stroke 
and thromboembolism
58
, carrying a 3-fold increased risk of stroke and mortality 
compared to arterial hypertension.
59
 An age-proportional ischemic stroke risk in non-
valvular AF patients has also been found.
58,59
  
 
Approved indications 
1- Stroke prevention in non-valvular atrial fibrillation 
Among anticoagulation indications, stroke prevention as a complication from AF is the 
widest and with greatest impact on public health. 
Concerning this, the non-inferiority clinical trial ROCKET AF
15
 demonstrated the 
efficacy of rivaroxaban vs warfarin in the prevention of the composite endpoint of 
stroke and systemic embolism in patients with non-valvular AF.  
A secondary analysis of the ROCKET AF study that compared the efficacy and safety 
results between warfarin and rivaroxaban in patients aged ≥75 vs <75, found that the 
positive benefit-risk profile of rivaroxaban relative to warfarin did not vary with age. 
In elderly patients on rivaroxaban there was a trend to increase the combined bleeding 
end point due to non-major bleeding, namely GI bleeding. Nevertheless the risk of 
intracranial hemorrhage was reduced, allowing us to conclude that the net clinical 
benefit of rivaroxaban compared with warfarin is more pronounced in elderly patients 
than in younger patients.
60 
In the ARISTOTLE
 
clinical trial apixaban was proved to be superior to warfarin in 
terms of efficacy and safety.
36
 
In the RE-LY study, 150 mg BID of dabigatran was superior to warfarin, with a similar 
overall major bleeding risk, despite the above mentioned increase in GI bleeding. The 
110 mg BID dose had similar efficacy, with the advantage of reducing by 20% the risk 
of major bleeding.
35   
An FDA Medicare analysis of a population over 65 years of age 
assigned to 150 mg BID or 75 mg BID (approved in the United States for patients with 
GFR between 15–30 mL/min) corroborated the RE-LY study results in terms of 
efficacy and safety.
61 
A 20% reduction on ischaemic strokes, a threefold lower rate of intracranial 
hemorrhagic complications and a 14% survival benefit were found. Although the major 
bleeding risk was equivalent to VKAs, a 28% increased risk of GI bleeding was 
associated to dabigatran. These findings were not extensible to the 16% of patients who 
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received dabigatran 75 mg BID, since in this group the outcomes were similar to 
warfarin’s, except for a lower rate of intracranial hemorrhage with dabigatran. 
Subgroup analyses stratified by age and gender showed that risk of major GI bleeding 
with the DTI was increased for women aged ≥ 75 and for men aged ≥ 85 vs warfarin. 
Surprisingly in women aged ≥ 85 there was a trend for a higher risk of death with 
dabigatran compared to warfarin, questioning the efficacy of the DTI in this subset of  
patients.
 61 
This specific group was barely represented in RE-LY and analyses of age 
and mortality were not reported. 
 
The positive efficacy and safety profile, namely a 28% prevention in stroke risk and a 
26% reduction in major bleedings, was also confirmed by another real world general 
practice study.
62 
A cohort study enrolling routine care patients also achieved better outcomes with the 
DTI and found a greater stroke reduction particularly among the subgroup of patients 
aged 75 or older.
63 
A Danish nationwide registry studied patients started on dabigatran, rivaroxaban or 
apixaban for stroke prophylaxis in atrial fibrillation vs warfarin. It was concluded that 
VKA initiation has declined consistently since the introduction of the NOACs. Older 
age, female gender and personal history of stroke were features associated with the use 
of NOAC, while CKD (which was the factor most strongly linked to warfarin use), 
myocardial infarction and heart failure were related to VKA utilization. The predicted 
thromboembolic risk and hemorrhagic risk was similar between users of NOACs and 
warfarin. 
The study inferred that treatment with NOACs is being consentaneous with guidelines 
recommendations.
64
 
 
The international GLORIA-AF registry also addressed this issue, showing that there is a 
widespread use of oral anticoagulation in North America and in Europe, predominantly 
NOACs.
65
 
This analysis highlighted that a significant amount of high-risk patients in North 
America and in Asia still receive antiplatelet treatment or have no antithrombotic 
therapy at all, albeit the percentage of treated patients with an indication for 
anticoagulation has risen comparing to previous registries.
66,67 
 
Edoxaban, initially introduced in Japan, received clearance from the FDA in January 
2015, based on the non-inferiority trial ENGAGE-AF TIMI-48.
30
 
It should be mentioned that patients with a GFR >95 ml/min (normal GFR according to 
the Kidney Disease Outcomes Quality Initiative criteria), presented an increased risk for 
ischemic stroke vs warfarin, therefore an alternative anticoagulant should be used. This 
finding may be explained by the fact that half the clearance of edoxaban is made by the 
kidney, which means that in patients with normal renal function the serum level of the 
drug, and consequently the efficacy, is inferior to that of patients with renal 
impairment.
19
  
Dabigatran was the only NOAC to be studied in AF patients with mechanical valvular 
prosthesis.
18,19,22
 The RE-ALIGN trial compared dabigatran (in doses that ranged from 
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150, 220 or 300 mg BID according to the GFR, aiming serum levels >50 ng/ml) with 
warfarin (adjusted to the target INR) in a population that underwent mechanical 
mitral/aortic valvuloplasty. The trial was stopped prematurely due to an increased risk 
of stroke, valvular thrombosis and bleeding (including major bleeding, namely 
hemopericardium) in the dabigatran arm.
68
 
 
2- Cardioversion in non-valvular AF 
X-VeRT was the first prospective randomized trial to compare a NOAC and VKA in 
patients with non-valvular AF undergoing elective electrical/chemical cardioversion. 
Rivaroxaban 20 mg/day (or 15 mg/day if GRF was 30-49 mL/min) reduced by 50% the 
risk of cardiovascular events (composite endpoint of stroke, transitory ischemic 
accident, systemic embolism, myocardial infarction and cardiovascular death), and by 
24% the risk of bleeding.
69
 Although the trial was not powered to achieve statistical 
significance, as it was designed to complement data from the ROCKET AF clinical 
trial, this indication was approved by the EMA. 
Dabigatran and apixaban are also approved for this indication, based on post hoc 
analysis of the RE-LY
70
 and ARISTOTLE
71 
trials, respectively. A recent meta-analysis 
corroborated these findings.
72
  
 
3- Treatment and prevention of venous thromboembolism 
DVT, its prevention and treatment, as well as its major complication pulmonary 
embolism (PE), both commonly referred to as VTE, are an indication to 
anticoagulate.
10,73
  
Aging is considered to be one of the most important and prevalent risk factors for 
developing VTE.
74
 
The trials that compared NOACs with conventional drugs for VTE treatment and 
prevention (heparin followed by VKA) were designed for non-inferiority. 
These trials included clinically stable PE patients and therefore there is no scientific 
evidence to support the use of NOACs in hemodynamically unstable 
PE.
28,75,76,77,78,79,80,81
 
The EINSTEIN-DVT
75
 and EINSTEIN-PE
76
 trials included patients with acute DVT or 
PE and compared rivaroxaban 15 mg BID for 3 weeks followed by 20 mg/day up to 3, 6 
or 12 months of treatment, with conventional treatment. The efficacy endpoint defined 
as recurrent DVT or PE and safety endpoint (bleeding) were similar between groups. 
An extrapolation of the EINSTEIN-DVT trial was made, and the patients completing 6–
12 months of treatment with the factor Xa inhibitor or VKA would continue to receive 
 12 
 
additional 6–12 months of rivaroxaban or placebo. Compared to the placebo group, 
patients treated with rivaroxaban had fewer recurrences of DVT but presented an 
increased risk of non-major bleedings.
75
  
Subgroup analysis from the EINSTEIN-DVT and EINSTEIN-PE pooled data found that 
fragile patients (defined as those aged > 75 years, CrCl < 50 ml/min or body weight ≤ 
50 Kg) treated with rivaroxaban had a substantial net clinical benefit and major bleeding 
reduction compared to traditional treatment.
82 
In the RE-COVER trial, patients with acute VTE were initially treated with heparin for 
5 to 10 days and afterwards received dabigatran 150 mg BID or warfarin. The rate of 
VTE recurrence and VTE-related mortality was similar in both arms. The overall 
bleeding risk and major bleeding rates were also comparable.
78
 
The RE-COVER II trial, with the same design as RE-COVER, confirmed the non-
inferiority of dabigatran.
79
  
In the RE-MEDY trial, a sample of RE-COVER patients that received a minimum of 3 
months of anticoagulation was selected and received additional treatment with warfarin 
or dabigatran for 6 to 36 months. The VTE recurrence rate was similar among groups 
but with less major bleedings in the dabigatran arm.
80
 
The RE-SONATE trial had a similar design but compared dabigatran with placebo. The 
VTE recurrence rate was similar among groups but there were more major bleedings in 
the dabigatran arm.
80
 
Additional data from the RE-COVER, RE-COVER II, RE-MEDY and RE-SONATE 
trials assured that age had no impact on recurrent VTE or hemorrhage outcomes.
79, 83 
The use of apixaban in VTE patients was evaluated in the AMPLIFY
80
 and AMPLIFY-
EXT
81
 trials.  
The AMPLIFY trial evaluated apixaban 10 mg BID during the first week followed by 5 
mg BID for 6 months vs standard of treatment (enoxaparin followed by warfarin) for a 
total of 6 months in the treatment of VTE. The risk of major bleeding was significantly 
inferior in the arm of the factor Xa inhibitor, with a 69% reduction.
80
 
In AMPLIFY-EXT two doses of apixaban, 2.5 mg BID and 5 mg BID were compared 
to placebo in patients previously treated for 6-12 months with conventional VTE 
anticoagulant treatment. By the end of the 12-month follow-up, the incidence of VTE, 
VTE-related, non VTE-related and overall mortalities were reduced with both doses of 
apixaban. Subgroup analysis found similar effectiveness with both doses of apixaban, 
nevertheless an increased risk of major and non-major bleeding was identified with both 
doses in patients aged > 75 years compared with placebo. 
81
 
The HOKUSAI-VTE trial included patients with acute DVT or PE and compared 
edoxaban to warfarin, after initial treatment with low molecular weight heparin 
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(LMWH) or unfractionated heparin. The duration of the treatment was 3-12 months and 
the VTE recurrence and VTE-related death rates were comparable between groups. In 
the group treated with the factor Xa inhibitor there was 19% less clinically relevant non-
major bleedings. No difference in the outcomes was found in the subgroup of patients 
aged > 75 years.
27
 
In paraneoplastic thrombosis there is a high VTE recurrence rate, as well as 
hemorrhagic complications.
84
 
Monotherapy with LMWH is the most effective treatment in paraneoplastic VTE, 
despite the inconvenience of the parenteral administration, weight and GFR related dose 
adjustments and bleeding complications.
84
 
In EINSTEIN-DVT and -PE trials approximately 5% of patients in each group had 
active cancer; the efficacy and safety results were comparable to the overall 
population.
75,76
 
In AMPLIFY and AMPLIFY EXT, only 2.6% and 1.7% of the patients (respectively) 
had active cancer.
80,81
 A subgroup analysis of the AMPLIFY trial demonstrated a 
reduction of VTE recurrence and a lower rate of bleeding
 
with apixaban.
81
 
In the dabigatran trials the percentage of patients with active cancer was about 4%, and 
a reduction of VTE recurrence was seen in the DTI group but the rate of bleeding 
complications was not reported.
77,78,85
 
The HOKUSAI-VTE trial included 2.5% of patients with active cancer, a reduction of 
VTE recurrence as well as major/non-major bleedings was reported in the edoxaban 
arm.
27
 
 
4- Secondary prevention of acute coronary syndrome  
Recently EMA has recommended rivaroxaban 2.5 mg BID for secondary prevention of 
acute coronary syndrome (ACS) based on the ATLAS ACS 2-TIMI 51 trial, in which 
the combination of the factor Xa inhibitor with dual antiplatelet therapy (acetylsalicylic 
acid and clopidogrel) vs placebo for patients with recent ACS reduced the composite 
primary efficacy endpoint of cardiovascular death, myocardial infarction and stroke, 
while increasing the risk of intracranial hemorrhage from 0.2 to 0.4%. The 5 mg BID 
dose triplicated that risk and therefore was not approved by the above mentioned 
Agency.
86
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Conclusion 
Despite the extensive evidence on the benefit of anticoagulating the elderly, this risk 
group is still undertreated. 
Predictable pharmacokinetics and pharmacodynamics, a rapid onset of action, 
significantly less food and pharmacological interactions, the absence of routine 
laboratory monitoring, as well as an improved efficacy/safety ratio, are clear advantages 
of NOACs compared to VKAs in this polymedicated and less compliant group. 
Considering that the main complication associated with antithrombotic treatment is 
intracranial hemorrhage and that NOACs have demonstrated to be superior to VKA in 
this endpoint, this probably is the strongest argument in favor of its use on a population 
prone to both thrombotic and bleeding events.  
Notwithstanding its large applicability, NOACs are contraindicated in valvular AF and 
there is no scientific evidence that support its use in hemodynamically-unstable PE. 
In paraneoplastic VTE the available evidence is insufficient to support its use, therefore 
further studies with follow-up periods greater than 6 months (as treatment is usually ad 
aeternum) are needed to address specifically patients with cancer and to compare 
NOAC with LMWH monotherapy. 
In a society where the elderly have an increasingly significant role, there is an urge to 
redefine social and therapeutic concepts, in order to invest in a non-prejudiced and 
evidence-based modus. 
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